Mitchell Keegan

1.0k total citations
22 papers, 802 citations indexed

About

Mitchell Keegan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mitchell Keegan has authored 22 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mitchell Keegan's work include Cancer Cells and Metastasis (4 papers), Diabetes and associated disorders (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). Mitchell Keegan is often cited by papers focused on Cancer Cells and Metastasis (4 papers), Diabetes and associated disorders (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). Mitchell Keegan collaborates with scholars based in United States, France and Netherlands. Mitchell Keegan's co-authors include Gordon C. Weir, Susan Bonner‐Weir, Jennifer Hollister‐Lock, Nitin Trivedi, Mahesh V. Padval, Changgeng Qian, Rudi Bao, Cheng-Jung Lai, Lisa M. Johansen and Margaret Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Endocrinology.

In The Last Decade

Mitchell Keegan

22 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell Keegan United States	12	409	252	194	121	110	22	802
Tserenchunt Gansukh Germany	14	278 0.7×	313 1.2×	138 0.7×	71 0.6×	88 0.8×	17	729
Kiyoko Kawahara Japan	16	359 0.9×	182 0.7×	85 0.4×	29 0.2×	71 0.6×	33	713
Isere Kuiatse United States	16	682 1.7×	268 1.1×	41 0.2×	72 0.6×	40 0.4×	36	946
Hassan Adwan Germany	18	390 1.0×	424 1.7×	94 0.5×	61 0.5×	61 0.6×	32	910
Beate Alinger Austria	19	490 1.2×	192 0.8×	76 0.4×	36 0.3×	48 0.4×	23	734
Franziska Arlt Germany	7	519 1.3×	301 1.2×	94 0.5×	67 0.6×	115 1.0×	7	848
NR Lemoine United Kingdom	7	360 0.9×	404 1.6×	49 0.3×	123 1.0×	81 0.7×	9	709
Nina Sausgruber Switzerland	8	478 1.2×	144 0.6×	42 0.2×	177 1.5×	103 0.9×	9	707
Htoo Zarni Oo Canada	21	743 1.8×	453 1.8×	151 0.8×	82 0.7×	147 1.3×	54	1.2k
Clara Salamanca Canada	12	382 0.9×	178 0.7×	88 0.5×	51 0.4×	70 0.6×	15	708

Countries citing papers authored by Mitchell Keegan

Since Specialization

Citations

This map shows the geographic impact of Mitchell Keegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Keegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Keegan more than expected).

Fields of papers citing papers by Mitchell Keegan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Keegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Keegan. The network helps show where Mitchell Keegan may publish in the future.

Co-authorship network of co-authors of Mitchell Keegan

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Keegan. A scholar is included among the top collaborators of Mitchell Keegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Keegan. Mitchell Keegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöffski, Patrick, Byoung Chul Cho, Antoîne Italiano, et al.. (2021). BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.. Journal of Clinical Oncology. 39(15_suppl). 3008–3008. 37 indexed citations

Gerber, David E., D. Ross Camidge, Daniel Morgensztern, et al.. (2019). Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 139. 60–67. 111 indexed citations

Schöffski, Patrick, Philippe Aftimos, Christophe Massard, et al.. (2019). A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS3162–TPS3162. 25 indexed citations

Keegan, Mitchell, Keith Wilcoxen, & Peter Ho. (2019). Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development. Cancer Research. 79(13_Supplement). 2199–2199. 9 indexed citations

Shimizu, Toshio, Kazuya Fukuoka, Masayuki Takeda, et al.. (2016). A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(5). 997–1003. 79 indexed citations

Gerber, David E., Suresh S. Ramalingam, Daniel Morgensztern, et al.. (2014). A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS8126–TPS8126. 5 indexed citations

Keegan, Mitchell, Vihren N. Kolev, Irina M. Shapiro, et al.. (2014). Vs-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells Directly and Through Inhibition of Tumor-Associated Macrophages and Cytokine Production. Annals of Oncology. 25. iv555–iv555. 3 indexed citations

Patel, Manish R., Jeffrey R. Infante, Kathleen N. Moore, et al.. (2014). Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.. Journal of Clinical Oncology. 32(15_suppl). 5521–5521. 24 indexed citations

Jones, Suzanne F., Kathleen N. Moore, Manish R. Patel, et al.. (2013). A phase I/IB study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer.. Journal of Clinical Oncology. 31(15_suppl). TPS2620–TPS2620. 3 indexed citations

10.

Xu, Qunli, Vihren N. Kolev, Quentin G. Wright, et al.. (2013). Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells.. Journal of Clinical Oncology. 31(15_suppl). e13523–e13523. 2 indexed citations

11.

Patel, Manish R., Jeffrey R. Infante, Kathleen N. Moore, et al.. (2013). Abstract A69: Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). A69–A69. 2 indexed citations

12.

Xu, Qiong, Vihren N. Kolev, Chantal Vidal, et al.. (2012). 400 FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in Vivo. European Journal of Cancer. 48. 122–122. 3 indexed citations

13.

Keegan, Mitchell, et al.. (2012). Abstract P6-11-07: The Cancer Stem Cell-Targeting Wnt Inhibitor VS-507 Reduces Breast Cancer Growth and Metastasis. Cancer Research. 72(24_Supplement). P6–11. 1 indexed citations

14.

Lai, Cheng-Jung, Rudi Bao, Xu Tao, et al.. (2010). CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity. Cancer Research. 70(9). 3647–3656. 182 indexed citations

15.

Shimizu, Takanori, A. W. Tolcher, Patricia LoRusso, et al.. (2010). 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. European Journal of Cancer Supplements. 8(7). 115–115. 5 indexed citations

16.

Lee, Margaret, Lisa M. Johansen, Yanzhen Zhang, et al.. (2007). The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action. Cancer Research. 67(23). 11359–11367. 90 indexed citations

17.

Fernandes, Justin R., Valérie F. Duvivier-Kali, Mitchell Keegan, et al.. (2004). Transplantation of islets transduced with CTLA4-Ig and TGFβ using adenovirus and lentivirus vectors. Transplant Immunology. 13(3). 191–200. 22 indexed citations

18.

Omer, Abdulkadir, Mitchell Keegan, Eva Czismadia, et al.. (2003). Macrophage depletion improves survival of porcine neonatal pancreatic cell clusters contained in alginate macrocapsules transplanted into rats. Xenotransplantation. 10(3). 240–251. 47 indexed citations

19.

Trivedi, Nitin, Jennifer Hollister‐Lock, María Dolores López-Ávalos, et al.. (2001). Increase in β-Cell Mass in Transplanted Porcine Neonatal Pancreatic Cell Clusters Is Due to Proliferation of β-Cells and Differentiation of Duct Cells*. Endocrinology. 142(5). 2115–2122. 64 indexed citations

20.

Trivedi, Nitin, Mitchell Keegan, Garry M. Steil, et al.. (2001). ISLETS IN ALGINATE MACROBEADS REVERSE DIABETES DESPITE MINIMAL ACUTE INSULIN SECRETORY RESPONSES1. Transplantation. 71(2). 203–211. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact